Metropolis Healthcare

Core acquisition adds to Metropolis Healthcare's long-term growth plans

Market share gains in the B2C portfolio are visible and Tier III+ markets are likely to contribute to the patient volume growth guidance

Axis Bank, Nippon AMC, Maruti: JM Financial picks 12 stocks to buy for 2025

From the robust banking and financial services domain, Axis Bank and Nippon AMC make the cut. The auto industry sees Maruti Suzuki and Samvardhana Motherson International (SAMIL) in the spotlight

Metropolis Healthcare shares rise 3% after acquiring Core Diagnostics

Shares of diagnostic firm Metropolis Healthcare surged 2.88 per cent at Rs 2,250 per share on the BSE in Tuesday's intraday trade

Stocks to Watch on Dec 10: Vi, Metropolis, MapmyIndia, TaMo, LIC, PFC

Stocks to Watch on Dec 10: From Vodafone Idea (Vi) to Tata Motors, here is a list of stocks that will remain in limelight today

Metropolis Healthcare adds Core strength to specialty cancer diagnostics

Buys 100% stake in Core Diagnostics through cash, stock for Rs 247 crore

Metropolis Healthcare to acquire Core Diagnostics for Rs 247 crore

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

Metropolis Healthcare plans to expand reach to 1,000 towns in 18 months

The firm aims to strengthen its presence in tier 2 and tier 3 cities, supported by an investment of approximately Rs 65 crore

Indian population saw 30% increase in ANAs post Covid-19, says study

ANAs are proteins produced by the immune system that mistakenly target the body's own cells, leading to tissue damage and autoimmune diseases like rheumatoid arthritis and thyroid disorders

Not looking to bring any strategic investor on board now: Ameera Shah

In a video interview with Sohini Das, Shah outlines her plans for international business, and also why she got in a new CEO

Patient influx, test volumes raise Metropolis Healthcare's profit by 31%

Commenting on the results, Ameera Shah, Executive Chairperson and Whole-time Director, Metropolis Healthcare, said that the company has consistently achieved high growth in patient volume

5 stocks with long buildup: AU SFB, Marico, TVS Motor may surge up to 22%

Aditya Birla Fashion, AU Small Finance Bank, Metropolis, Marico and TVS Motor have seen steady rise in stock price, backed by rise in open interest, thus indicating long buildup at these counters in t

Metropolis Health up 8% post Q4 nos; Ameera appointed Executive Chairperson

Metropolis Health stock update: Metropolis Healthcare stock price hit a fresh record high of Rs 2,049 on Wednesday. Ameera Shah takes charge as executive chairperson and whole-time director

RIL, Sun Pharma, HDFC Bank, BHEL among 11 stocks to monitor on May 22

At 7:09 AM, GIFT Nifty futures indicated a modest uptick of 25 points, trading at 22,626 against Nifty futures

Metropolis Healthcare revenue up 17%, targets industry-leading growth

In Q4, the business-to-consumers (B2C) revenues grew by approximately 20 per cent Y-o-Y, and revenues from the Mumbai market also saw 20 per cent growth

Metropolis Healthcare gets Rs 24 cr income tax demand from Mumbai officials

Metropolis Healthcare Ltd on Monday said it has received a Rs 24.46 crore income tax demand from the income tax authority. An income tax demand of Rs 24.46 crore (tax plus interest) has been raised by the Assistant Commissioner of Income Tax, Mumbai, Income Tax Department (ACIT) for assessment year (AY) 2023-24, Metropolis Healthcare said in a regulatory filing. The actual demand for AY 2023-24 will come to Rs 24.19 crore after adjusting rectification of Rs 27 lakh pertaining to AY 2023-24, it added. For the Rs 27 lakh demand, tax plus interest, for AY 2023-24, the company has brought to the notice of ACIT that an error has occurred during the computation of tax and ACIT has not granted credit for certain taxes already paid by the company. Metropolis Healthcare further said it has filed an application for rectification and issuance of the rectification order on account of TDS credit, advance tax, and self-assessment tax credits not allowed. ACIT has accepted the application and is

Metropolis Healthcare Q3 results: PAT down 24% due to Chennai floods

On a sequential basis, the company exhibited a 5.63 per cent decline in revenue along with PAT, which declined by 23.41 per cent

Metropolis Healthcare PAT declines 12%, consolidated revenue up 2.7%

EBITDA stood at Rs 77.8 crore, declining 6.2 per cent year-on-year and growing 16.1 per cent sequentially

Metropolis Healthcare eyes 60% revenue from B2C business in next 2-3 years

The diagnostic player has also taken price hikes in the range of 4-5 percent in the last three years

Metropolis Healthcare net profit declines 15% to Rs 29 crore in Q1

Metropolis Healthcare on Thursday said its net profit declined 15 per cent to Rs 29 crore for the first quarter ended June 30, 2023. The diagnostics firm had reported a net profit of Rs 34 crore in the April-June quarter of the last fiscal. Revenue from operations declined to Rs 277 crore from Rs 280 crore in the year-ago period, Metropolis Healthcare said in a statement. Metropolis Healthcare Promoter and Managing Director Ameera Shah said the company remains optimistic about scaling up revenue in the upcoming quarters, indicating positive operating leverage play. "Going forward, company focuses on network expansion, increasing doctor connects, growing specialised & wellness segments and upgrading IT infrastructure for enhancing the consumer experience," she added.

AI cannot replace human knowledge: Metropolis Healthcare Promoter & MD

In 2021-22, Covid19 business was almost 20-22% of the revenue for most diagnostic companies. The non-Covid19 business is not going to grow by 22% to make it equal